Lifecore Biomedical Inc LFCR.OQ LFCR.O is expected to report resultson April 3 for the period ending February 28 2025
The Chaska Minnesota-based company is expected to report revenue of $33.229 million, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lifecore Biomedical Inc is for a loss of 15 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lifecore Biomedical Inc is $10.00, above its last closing price of $7.04.
This summary was machine generated April 1 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.